scholarly journals Chondrogenic Potential of Pellet Culture Compared to High-Density Culture on a Bacterial Cellulose Hydrogel

2020 ◽  
Vol 21 (8) ◽  
pp. 2785
Author(s):  
Nele Pascale Grigull ◽  
Julia Isabelle Redeker ◽  
Bärbel Schmitt ◽  
Maximilian Michael Saller ◽  
Veronika Schönitzer ◽  
...  

Cell-based approaches of cartilage lesions use different culture systems to obtain optimal cell quality. Pellet cultures with high cellular density (HD) are the gold standard to keep chondrocytes in a differentiated stage. Bacterial cellulose (BC) hydrogel is discussed to prevent cellular aging and dedifferentiation. The hypothesis of this study was that HD culture on BC hydrogel (HD hydrogel) might reach the chondrogenic potential of pellet culture (pellet). Human articular osteoarthritic (OA) and non-osteoarthritic (non-OA) chondrocytes were cultured for seven days within pellets and compared to HD hydrogel and HD polystyrene. Gene expression analysis and histological assessment were performed. We observed no significant change of COL2A1 expression by the culture system (pellet, HD hydrogel and HD polystyrene) but a significant change of COL2A1/COL1A1-ratio, with the highest ratio in pellets. Chondrocytes on HD hydrogel showed an elevated expression of MMP13 and on polystyrene an increased expression of COL1A1 and MMP13. The patterns of gene expression changes observed in OA and non-OA chondrocytes in reaction to the different culture systems were similar in those two cell groups. Pellet cultures moreover formed a histomorphologically superior neocartilage. Concluding, human chondrocytes kept the potential to express COL2A1 in all HD culture systems. However, pellets excelled in a higher COL2A1/COL1A1-ratio, a higher extracellular matrix deposit and in not developing degeneration and dedifferentiation markers. This underlines the superiority of pellet culture in maintaining the chondrogenic potential of human chondrocytes in vitro.

2017 ◽  
Vol 14 (2) ◽  
pp. 103-112 ◽  
Author(s):  
Suhaeb A. Mahmod ◽  
Simmrat Snigh ◽  
Ivan Djordjevic ◽  
Yong Mei Yee ◽  
Rohana Yusof ◽  
...  

2021 ◽  
Vol 29 ◽  
pp. S211-S212
Author(s):  
I. Uzieliene ◽  
E. Bagdonas ◽  
J. Denkovskij ◽  
E. Bernotiene ◽  
H.-J. Yoon ◽  
...  

2017 ◽  
Vol 118 (07) ◽  
pp. 386-390 ◽  
Author(s):  
K. O. Yaykasli ◽  
O. F. Hatipoglu ◽  
E. Yaykasli ◽  
E. Kaya ◽  
M. Ozsahin ◽  
...  

2011 ◽  
Vol 3 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Yue Zhang ◽  
Zulma Gazit ◽  
Gadi Pelled ◽  
Dan Gazit ◽  
Gordana Vunjak-Novakovic

2015 ◽  
Vol 23 ◽  
pp. A196-A197
Author(s):  
K. Alvarez ◽  
M.C. de Andres ◽  
A. Takahashi ◽  
R.O. Oreffo

Genome ◽  
1989 ◽  
Vol 31 (1) ◽  
pp. 386-389 ◽  
Author(s):  
James R. Smith ◽  
Olivia M. Pereira-Smith

The limited division potential of normal human diploid fibroblasts in culture represents a model system for cellular aging. Observations indicate cellular senescence is an active process. Senescent cells, although unable to divide, are actively metabolizing. Hybrids from fusion of normal and immortal human cells exhibit limited division potential, suggesting that the phenotype of cellular senescence is dominant and supporting the hypothesis that senescence is genetically programmed. Fusion of immortal human cell lines with each other has identified four complementation groups for indefinite division. This indicates that a limited number of specific genes or processes are involved in senescence. Senescent cells express highly abundant DNA synthesis inhibitory messenger RNAs and produce a surface membrane associated protein inhibitor of DNA synthesis not expressed in young cells. Senescent cell membranes were used as immunogen to generate three monoclonal antibodies reacting specifically with senescent but not young cells in several normal human cell lines. We have also found that fibronectin messenger RNA accumulates to high levels in senescent cells. The role of these changes in gene expression in senescence is being explored.Key words: cellular senescence, human cells.


1991 ◽  
Vol 35 (2) ◽  
Author(s):  
Taku Matsushita ◽  
Hiromichi Hidaka ◽  
Ken-ichi Kamihata ◽  
Yasuhiko Kawakubo ◽  
Kazumori Funatsu

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 166-166
Author(s):  
David Kosoff ◽  
Leigh Ellis ◽  
David J. Beebe ◽  
Joshua Michael Lang

166 Background: Cytotoxic T lymphocytes (CTLs) perform vital anti-tumor functions and are critical to the efficacy of many anticancer therapies. In prostate cancer, the characteristic paucity of activated CTLs within the tumor microenvironment (TME) may be a key factor in disease progression and likely underlies the limited role for immune checkpoint inhibitors (ICIs) in prostate cancer treatment. In this study, we utilized novel microfluidic technologies to evaluate whether TAMs may be driving the exclusion of T cells from the prostate TME and whether the immunosuppressive functions of TAMs could be modified by epigenetic modifying agents. Methods: Primary macrophages and autologous T cells were derived from peripheral blood samples of prostate cancer patients at the University of Wisconsin. Mono-, co-, and tri-culture systems of macrophages, T cells, and 22RV1 cells (androgen-dependent prostate cancer cell line) were cultured in 2D and 3D in microfluidic cell culture platforms. Culture systems were treated with the EZH2 inhibitors (EZH2i) DZNep or EPZ-6438 or left untreated. Macrophages were also treated with M1 (IFN-g) and M2 (IL-4) polarizing cytokines. Systems were analyzed for T cell migration as well as mRNA and protein expression in each cell population. Results: Autologous macrophages inhibited activated T cell migration towards tumor cells in a multi-cellular microscale TME. T cell migration was restored through treatment with EZH2i. Gene expression analysis identified that EZH2i altered macrophage gene expression in the unpolarized and M1/M2 polarized states. In particular, there was increased expression of genes involved in T cell recruitment/chemotaxis, including CXCL10, CXCL11, CXCL12, following EZH2i treatment. Conclusions: We used novel microfluidic technologies to model and analyze multicellular TMEs using primary, patient-derived cells. We demonstrate that TAM-mediated suppression of T cell migration is mediated, in part, through epigenetic pathways, which can be targeted with EZH2i. Treatment with EZH2i, alone or in combination other therapies such as ICIs, may enhance cytotoxic T cell migration and activity in primary prostate cancer.


Sign in / Sign up

Export Citation Format

Share Document